Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma
The DOI matches its Crossref record; 34 of the 35 references it cites were found in a registry or an index.
Abstract
While initial therapies have become highly effective with introduction of lenalidomide and bortezomib and patients may opt for delayed stem cell transplantation, it is important to collect stem cells for future transplant. Given its increasing use as initial therapy, we examined if lenalidomide had any impact on the ability to collect peripheral blood stem cells (PBSC). We studied the entire cohort of patients with myeloma undergoing PBSC mobilization at our institution during a 5-year period, comparing the results between patients receiving different initial therapies. Among those mobilized with granulocyte-colony stimulating factor (G-CSF) alone, there was a significant decrease in total CD34(+) cells collected (P<0.001), average daily collection (P<0.001), day 1 collection (P<0.001) and increased number of aphereses (P=0.004) in patients treated with lenalidomide compared to those receiving dexamethasone, thalidomide-dexamethasone or VAD. A similar trend was seen in those mobilized with chemotherapy and G-CSF. A trend was seen towards decreased PBSC yield with increasing duration of lenalidomide therapy as well as increasing age (P=0.002). There was no effect on quality of PBSC collected based on similar engraftment across all groups. We recommend collection of PBSC within 6 months of initiation of therapy with lenalidomide containing regimens to minimize the risk of mobilization failures.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Stem cell collection with granulocyte stimulating factor (G-CSF) alone may be impaired when lenalidomide is used as induction therapy.112”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [112]
In the citing paper
“This issue can often be overcome using high-dose cyclophosphamide or the CXCR4 antagonist plerixafor125.”
From Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide (2021) · cites this paper as [125]
Citations
Cites
A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
Richardson, P. G., Barlogie, B., Berenson, J., Singhal, S., Jagannath, S., Irwin, D., Rajkumar, S. V., Srkalovic, G., Alsina, M., Alexanian, R., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030288 · Cited by 2,632
Self-citationAttal, M., Harousseau, J.-L., Stoppa, A.-M., Sotto, J.-J., Fuzibet, J.-G., Rossi, J.-F., Casassus, P., Maisonneuve, H., Facon, T., Ifrah, N., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199607113350204 · Cited by 2,548
Ttal, M. I. A., Ean, J., Dünne, A. A., Toppa, A. S., Ossi, R. G., Hilippe, P., Asassus, C., Acon, T. H. F., Orbert, N., Ayen, C. A. P., et al. (2013) · Cited by 2,161
High-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for Multiple Myeloma
Child, J. A., Morgan, G. J., Davies, F. E., Owen, R. G., Bell, S. E., Hawkins, K., Brown, J., Drayson, M. T., & Selby, P. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022340 · Cited by 1,768 · cited 1×
“dtd"[ ]> Introduction High-dose therapy and autologous stem cell transplantation has been an important part of myeloma therapy ever since the initial randomized trials demonstrated a survival benefit for the procedure compared to conventional chemotherapy”
BackgroundSingle versus Double Autologous Stem-Cell Transplantation for Multiple Myeloma
Attal, M., Harousseau, J.-L., Facon, T., Guilhot, F., Doyen, C., Fuzibet, J.-G., Monconduit, M., Hulin, C., Caillot, D., Bouabdallah, R., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa032290 · Cited by 984 · cited 1×
“11 Recent advances in the field, including the potential impact of tandem stem cell transplant and introduction of very effective agents such as bortezomib and lenalidomide have changed the landscape of treatment of myeloma”
BackgroundRajkumar, S. V., Blood, E., Vesole, D., Fonseca, R., & Greipp, P. R. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.0221 · Cited by 865
Self-citationSingle versus Double Autologous Stem-Cell Transplantation for Multiple Myeloma
(2004) · New England Journal of Medicine · doi:10.1056/nejm200406173502526 · Cited by 817
Multiple Myeloma: Diagnosis and Treatment
Rajkumar, S. V., & Kumar, S. (2016) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2015.11.007 · Cited by 812
Self-citationCombination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma
Rajkumar, S. V., Hayman, S. R., Lacy, M. Q., Dispenzieri, A., Geyer, S. M., Kabat, B., Zeldenrust, S. R., Kumar, S., Greipp, P. R., Fonseca, R., et al. (2005) · Blood · doi:10.1182/blood-2005-07-2817 · Cited by 648
Self-citationProteasome Inhibition As a Novel Therapeutic Target in Human Cancer
Rajkumar, S. V., Richardson, P. G., Hideshima, T., & Anderson, K. C. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.11.030 · Cited by 569
Self-citation
Cited by
Items 101–200 of 351
Recent advances of IMiDs in cancer therapy
Li, S., Gill, N. K., & Lentzsch, S. (2010) · Current Opinion in Oncology · doi:10.1097/cco.0b013e32833d752c · Cited by 35
Tosi, P., Zamagni, E., Tacchetti, P., Ceccolini, M., Perrone, G., Brioli, A., Pallotti, M. C., Pantani, L., Petrucci, A., Baccarani, M., et al. (2010) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2010.02.020 · Cited by 34
Impact of lenalidomide on the functional properties of human mesenchymal stromal cells
Wobus, M., Benath, G., Ferrer, R. A., Wehner, R., Schmitz, M., Hofbauer, L. C., Rauner, M., Ehninger, G., Bornhäuser, M., & Platzbecker, U. (2012) · Experimental Hematology · doi:10.1016/j.exphem.2012.06.004 · Cited by 34
Bortezomib in multiple myeloma
Terpos, E., Ρούσσου, Μ., & Dimopoulos, M. A. (2008) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.4.5.639 · Cited by 37
“The IFM 2005/01 trial, analysing data from the first 222 patients, reports a post-induction CR + nCR rate of 22% with bortezomib plus dexamethasone (Vel-Dex), compared to 9% with VAD, and post-SCT response rates of 38 versus 28%, respectively (p = NS) [55] .”
BackgroundInfluentialRecent advances in the management of multiple myeloma.
Kumar, L., Verma, R. K., & Radhakrishnan, V. S. (2010) · PubMed · Cited by 36
Chen, A. I., Bains, T., Murray, S. N., Knight, R., Shoop, K. M., Bubalo, J. S., Fowler, C., Slater, S., & Maziarz, R. T. (2012) · Bone Marrow Transplantation · doi:10.1038/bmt.2012.74 · Cited by 33
Lonial, S., & Cavenagh, J. D. (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2009.07649.x · Cited by 35
“…and recommendations that minimise the risk of mobilisation failure include limiting the duration of lenalidomide treatment prior to stem-cell collection (Kumar et al, 2007b; Paripati et al, 2008), and using cyclophosphamide to mobilise following lenalidomide exposure (Mazumder et al, 2008).”
BackgroundVeltri, L. W., Cumpston, A., Shillingburg, A., Wen, S., Jin, L., Leadmon, S., Watkins, K., Craig, M., Hamadani, M., & Kanate, A. S. (2015) · Cytotherapy · doi:10.1016/j.jcyt.2015.09.002 · Cited by 35
Nazha, A., Cook, R., Vogl, D. T., Mangan, P. A., Gardler, M., Hummel, K., Cunningham, K., Luger, S. M., Porter, D., Schuster, S. J., et al. (2010) · Bone Marrow Transplantation · doi:10.1038/bmt.2010.63 · Cited by 36
Mobilization of hematopoietic stem cells into the peripheral blood
Damon, L. E., & Damon, L. E. (2009) · Expert Review of Hematology · doi:10.1586/ehm.09.54 · Cited by 35
Giebel, S., Krużel, T., Czerw, T., Saduś‐Wojciechowska, M., Najda, J., Chmielowska, E., Grosicki, S., Jurczyszyn, A. J., Pasiarski, M., Nowara, E., et al. (2013) · Bone Marrow Transplantation · doi:10.1038/bmt.2012.269 · Cited by 31
Oakervee, H. E., Popat, R., & Cavenagh, J. D. (2007) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190701540991 · Cited by 33
“In a recent retrospective analysis of 376 patients from the Mayo Clinic, patients treated with lenalidomide plus dexamethasone had both lower yields of CD34þ cells and required more aphereses to achieve prespecified collection goals compared with those treated with single-agent dexamethasone, thalidomide plus dexameth…”
ResultInfluentialHow do we mobilize and collect autologous peripheral blood stem cells?
Yuan, S., & Wang, S. (2016) · Transfusion · doi:10.1111/trf.13868 · Cited by 31
Induction Therapy in Multiple Myeloma
Harousseau, J. (2008) · Hematology · doi:10.1182/asheducation-2008.1.306 · Cited by 32
Uy, G. L., Goyal, S. D., Fisher, N. M., Oza, A. Y., Tomasson, M. H., Stockerl-Goldstein, K. E., DiPersio, J. F., & Vij, R. (2008) · Bone Marrow Transplantation · doi:10.1038/bmt.2008.384 · Cited by 30
Li, S., Fu, J., Hui, M., Mapara, M. Y., & Lentzsch, S. (2012) · Leukemia · doi:10.1038/leu.2012.323 · Cited by 29
Bhutani, D., Zonder, J. A., Valent, J. N., Tageja, N., Ayash, L. J., Deol, A., Al-Kadhimi, Z. S., Abrams, J., Lum, L. G., Ratanatharathorn, V., et al. (2013) · Supportive Care in Cancer · doi:10.1007/s00520-013-1808-5 · Cited by 29
How lenalidomide is changing the treatment of patients with multiple myeloma
Dimopoulos, M. A., Terpos, E., & Niesvizky, R. (2013) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2013.05.013 · Cited by 30
“[69] Kumar S, Dispenzieri A, Lacy MQ, et al.”
BackgroundBrioli, A., Perrone, G., Patriarca, F. F., Pezzi, A., Nobile, F., Ballerini, F., Motta, M. R., Ronconi, S., Tacchetti, P., Catalano, L., et al. (2015) · Bone Marrow Transplantation · doi:10.1038/bmt.2014.322 · Cited by 31
Alexander, E. T., Towery, J. A., Miller, A. N., Kramer, C., Hogan, K. R., Squires, J. E., Stuart, R. K., & Costa, L. J. (2011) · Transfusion · doi:10.1111/j.1537-2995.2011.03085.x · Cited by 32
Peripheral Blood Stem Cell Mobilization Tactics
Rosenbeck, L. L., Srivastava, S., & Kiel, P. J. (2010) · Annals of Pharmacotherapy · doi:10.1345/aph.1m289 · Cited by 28
Wang, L., Xiang, H., Yan, Y., Deng, Z., Li, H., Li, X., & Liu, J. (2021) · Annals of Hematology · doi:10.1007/s00277-020-04376-w · Cited by 28
McCaughan, G. J. B., Gandolfi, S., Moore, J. J., & Richardson, P. G. G. (2022) · British Journal of Haematology · doi:10.1111/bjh.18295 · Cited by 29
Shaughnessy, P. J., Chao, N. J. A., Shapiro, J., Walters, K., McCarty, J. M., Abhyankar, S., Shayani, S., Helmons, P. J., Leather, H. L., Pazzalia, A., et al. (2013) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2013.05.008 · Cited by 29
Shah, E. E., Young, R. P., Wong, S. W. K., Damon, L. E., Wolf, J. L., Shah, N. D., Leavitt, A. D., Loeffler, P., & Martin, T. G. (2019) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2019.11.024 · Cited by 26
Optimizing mobilization strategies in difficult-to-mobilize patients: The role of plerixafor
Göker, H., Etgül, S., & Büyükaşık, Y. (2015) · Transfusion and Apheresis Science · doi:10.1016/j.transci.2015.05.011 · Cited by 25
“Furthermore, Lenalidomide is also associated with an increased risk of mobilization failure especially after receiving 4 or more cycles [68,69].”
BackgroundAntar, A., Otrock, Z. K., Kharfan‐Dabaja, M. A., Ghaddara, H. A., Kreidieh, N., Mahfouz, R. A., & Bazarbachi, A. A. (2015) · Bone Marrow Transplantation · doi:10.1038/bmt.2015.23 · Cited by 25
Autologous stem cell transplantation in multiple myeloma
Ricciuti, G., Falcone, A. P., Cascavilla, N., Martinelli, G., & Cerchione, C. (2021) · Panminerva Medica · doi:10.23736/s0031-0808.20.04114-2 · Cited by 28
Johnsrud, A. J., Ladha, A., Muffly, L. S., Shiraz, P., Goldstein, G., Osgood, V., Shizuru, J. A., Johnston, L., Arai, S., Weng, W., et al. (2021) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2021.04.016 · Cited by 24
Thalidomide, lenalidomide and bortezomib in the management of newly diagnosed multiple myeloma
Laubach, J. P., Schlossman, R. L., Mitsiades, C. S., Anderson, K. C., & Richardson, P. G. G. (2011) · Expert Review of Hematology · doi:10.1586/ehm.10.83 · Cited by 25
Stem-cell transplantation in multiple myeloma: how far have we come?
Soekojo, C. Y., & Kumar, S. K. (2019) · Therapeutic Advances in Hematology · doi:10.1177/2040620719888111 · Cited by 27
Self-citationA concise review on factors influencing the hematopoietic stem cell transplantation main outcomes
Rafiee, M., Abbasi, M., Rafieemehr, H., Mirzaeian, A., Barzegar, M., Amiri, V., Shahsavan, S., & Mohammadi, M. H. (2021) · Health Science Reports · doi:10.1002/hsr2.282 · Cited by 24
Kumar, S. K., Mikhael, J., LaPlant, B. R., Lacy, M. Q., Buadi, F. K., Dingli, D., Gertz, M. A., Laumann, K. M., Miceli, T. S., Mahlman, M., et al. (2013) · Bone Marrow Transplantation · doi:10.1038/bmt.2013.175 · Cited by 24
Self-citationPractical Approaches to the Use of Lenalidomide in Multiple Myeloma: A Canadian Consensus
Reece, D. E., Kouroukis, C. T., LeBlanc, R., Sébag, M., Song, K., & Ashkenas, J. (2012) · Advances in Hematology · doi:10.1155/2012/621958 · Cited by 23
Autologous hematopoietic cell transplantation: An update for clinicians
Hamadani, M. (2014) · Annals of Medicine · doi:10.3109/07853890.2014.952662 · Cited by 27
Identification of prognostic factors for plerixafor‐based hematopoietic stem cell mobilization
Basak, G. W., Jakšić, O., Kořístek, Z., Mikala, G., Mayer, J., Masszi, T., Labar, B., Wiktor-Jędrzejczak, W., & for the Central and Eastern European Leukemia Group (CELG) (2011) · American Journal of Hematology · doi:10.1002/ajh.22038 · Cited by 23
Moreb, J. S., Salmasinia, D., Hsu, J. W., Hou, W., Cline, C. L., & Rosenau, E. H. (2011) · Advances in Hematology · doi:10.1155/2011/517561 · Cited by 23
“Prior treatment with lenalidomide has been reported to increase the risk of poor mobilization significantly in MM patients [31, 32].”
BackgroundRaje, N. S., Hideshima, T., Yee, A. J., & Anderson, K. C. (2017) · Wiley eBooks · doi:10.1002/9781119000822.hfcm122 · Cited by 23
Lenalidomide in multiple myeloma: an evidence-based review of its role in therapy
Richardson, P. G. G., Mitsiades, C., Laubach, J., Schlossman, R., Ghobrial, I., Hideshima, T., Munshi, N., & Anderson, K. (2009) · Core evidence · doi:10.2147/ce.s6002 · Cited by 25
“Stem cell transplantation Stem cell collection Lenalidomide plus dexamethasone In MM patients who received initial therapy with lenalidomide plus dexamethasone, a retrospective analysis of a five-year treatment period at a single institution indicated there was a trend towards decreased peripheral blood stem cell yiel…”
Samaras, P., Pfrommer, S., Seifert, B., Petrausch, U., Mischo, A., Schmidt, A., Schanz, U., Nair, G., Bargetzi, M. J., Taverna, C., et al. (2014) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2014.09.020 · Cited by 21
Baertsch, M., Schlenzka, J., Lisenko, K., Krzykalla, J., Becker, N., Weisel, K. C., Noppeney, R., Martin, H., Lindemann, H., Haenel, M., et al. (2017) · European Journal Of Haematology · doi:10.1111/ejh.12888 · Cited by 21
Does stem cell transplantation have a role in the management of multiple myeloma, 2009?
Gertz, M. A., & Buadi, F. K. (2008) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560802636839 · Cited by 21
“This is particularly important given recent evidence that lenalidomide may reduce the yield of stem cells in patients with multiple myeloma [23] .”
BackgroundSelf-citationTherapeutic approaches for newly diagnosed multiple myeloma patients in the era of novel drugs
Morabito, F., Gentile, M., Mazzone, C., Bringhen, S., Vigna, E., Lucia, E., Recchia, A. G., Raimondo, F. D., Musto, P., & Palumbo, A. (2010) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2010.01472.x · Cited by 20
“Moreover, lenalidomide decreases peripheral CD34 + stem cell concentration to a greater extent than does thalidomide (58).”
BackgroundLenalidomide in multiple myeloma: current experimental and clinical data
Cives, M., Milano, A., Dammacco, F., & Silvestris, F. (2012) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2011.01735.x · Cited by 21
“However, despite the recorded increase in both ORR and PFS in the LEN-receiving arm, the evidence that IMiDs affect stem cell mobilization in ASCT apparently suggested a reduction in the number of monthly LEN cycles (usually up to 4) before stem cell harvesting (38, 39).”
BackgroundMultiple myeloma: improved outcomes with new therapeutic approaches
Eshaghian, S., & Berenson, J. R. (2012) · Current Opinion in Supportive and Palliative Care · doi:10.1097/spc.0b013e3283565c56 · Cited by 20
“The previous concern that lenalidomide’s hematological toxicity could negatively affect stem cell mobilization [79] has also been shown to be not important clinically.”
BackgroundMultiple Myeloma: Updates on Diagnosis and Management.
Jewell, S. W., Xiang, Z., Kunthur, A., & Mehta, P. (2015) · Europe PMC (PubMed Central) · Cited by 24
Auner, H. W., Mazzarella, L., Cook, L. B. M., Szydlo, R., Saltarelli, F., Pavlů, J., Bua, M., Giles, C. M., Apperley, J. F., & Rahemtulla, A. (2010) · Bone Marrow Transplantation · doi:10.1038/bmt.2010.141 · Cited by 20
Bal, S., Landau, H. J., Shah, G. L., Scordo, M., Dahi, P. B., Lahoud, O. B., Hassoun, H., Hultcrantz, M. L., Korde, N., Lendvai, N. K., et al. (2020) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2020.04.011 · Cited by 23
Shimazu, Y., Mizuno, S., Fuchida, S., Suzuki, K., Tsukada, N., Hanagaishi, A., Itagaki, M., Kataoka, K., Kako, S., Sakaida, E., et al. (2021) · Cancer Science · doi:10.1111/cas.15163 · Cited by 20
Late Afternoon Dosing of Plerixafor for Stem Cell Mobilization: A Practical Solution
COOPER, D. L., Pratt, K., Baker, J., Medoff, E., Conkling-Walsh, A., Foss, F. M., Snyder, E., Yen, W., & Seropian, S. (2011) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2011.03.014 · Cited by 20
Venglár, O., Kapustová, V., Sithara, A. A., Žihala, D., Muroňová, L., Ševčíková, T., Vrana, J., Vdovin, A., Radocha, J., Krhovská, P., et al. (2023) · British Journal of Haematology · doi:10.1111/bjh.19141 · Cited by 21
Abusin, G. A., Abu‐Arja, R., Gingrich, R., Magalhaes-Silverman, M. D., Zamba, G. K. D., & Schlueter, A. J. (2013) · Journal of Clinical Apheresis · doi:10.1002/jca.21256 · Cited by 19
“Multiple studies have demonstrated the negative impact of lenalidomide therapy on stem cell mobilization [29,30].”
BackgroundImmunomodulatory drugs in multiple myeloma: from molecular mechanisms of action to clinical practice
Castelli, R., Cannavò, A., Conforti, F., Grava, G., & Cortelezzi, A. (2012) · Immunopharmacology and Immunotoxicology · doi:10.3109/08923973.2012.658921 · Cited by 19
Sheppard, D., Bredeson, C., Huebsch, L. B., Allan, D., & Tay, J. (2014) · Bone Marrow Transplantation · doi:10.1038/bmt.2014.33 · Cited by 19
Specialty pharmacy for hematologic malignancies
Fajardo, S., Zook, F., & Dotson, E. K. (2016) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp150749 · Cited by 20
Lin, T., Wang, P., Kuo, M., Hung, Y., Chang, H., & Tang, T. (2015) · Journal of Clinical Apheresis · doi:10.1002/jca.21421 · Cited by 19
Misawa, S., & Kuwabara, S. (2013) · Clinical and Experimental Neuroimmunology · doi:10.1111/cen3.12052 · Cited by 19
Plerixafor for mobilization of blood stem cells in autologous transplantation: an update
Jantunen, E., & Varmavuo, V. (2014) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2014.902927 · Cited by 18
“In myeloma patients, the use of lenalidomide before mobilization is known to be associated with inferior mobilization of CD34 cells [35,36].”
BackgroundThe evolving role of plerixafor in hematopoietic progenitor cell mobilization
Tanhehco, Y. C., Vogl, D. T., Stadtmauer, E. A., & O’Doherty, U. (2013) · Transfusion · doi:10.1111/trf.12102 · Cited by 19
Özsan, G. H., Micallef, I. N., Dispenzieri, A. A., Kumar, S. K., Lacy, M. Q., Dingli, D., Hayman, S. R., Buadi, F. K., Wolf, R. C., Gastineau, D. A., et al. (2011) · American Journal of Hematology · doi:10.1002/ajh.22179 · Cited by 18
Self-citationFront-Line Treatment in Younger Patients With Multiple Myeloma
Rajkumar, S. V., & Sonneveld, P. (2009) · Seminars in Hematology · doi:10.1053/j.seminhematol.2009.02.005 · Cited by 18
Self-citationA case of severe aplastic anemia secondary to treatment with lenalidomide for multiple myeloma
Dasanu, C. A., & Alexandrescu, D. T. (2008) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2008.01176.x · Cited by 18
“(2) reported a statistically significant decrease in the stem cell yield from myeloma patients after pretransplant induction therapy with lenalidomide, compared to the stem cell yield after induction with other antimyeloma agents.”
ResultManagement of mobilization failure in 2017
Namdaroğlu, S., Korkmaz, S., & Altuntaş, F. (2017) · Transfusion and Apheresis Science · doi:10.1016/j.transci.2017.11.017 · Cited by 18
“[29] Kumar S, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Gastineau DA, et al.”
BackgroundPeripheral blood stem cell mobilization in multiple myeloma: Growth factors or chemotherapy?
Wallis, W. D., & Qazilbash, M. H. (2017) · World Journal of Transplantation · doi:10.5500/wjt.v7.i5.250 · Cited by 18
Turunen, A., Silvennoinen, R. H., Partanen, A., Valtola, J., Siitonen, T., Putkonen, M., Sankelo, M., Pyörälä, M., Kuittinen, T., Penttilä, K., et al. (2021) · Transfusion · doi:10.1111/trf.16424 · Cited by 17
“The use of lenalidomide prior to graft collection may hamper stem cell mobilization.(5,6) Mobilization with cyclophosphamide (CY) and granulocyte colony-stimulating factor (G-CSF) results in higher CD34 yields than mobilization with G-CSF alone.”
BackgroundLenalidomide and its role in the management of multiple myeloma
Falco, P., Cavallo, F., Larocca, A., Liberati, A. M., Musto, P., Boccadoro, M., & Palumbo, A. (2008) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.8.6.865 · Cited by 17
Current Standards for First-Line Therapy of Multiple Myeloma
Jagannath, S. (2007) · Clinical Lymphoma & Myeloma · doi:10.3816/clm.2007.s.024 · Cited by 18
Review of therapy for relapsed/refractory multiple myeloma: focus on lenalidomide
Mariz, J., & Esteves, G. V. (2012) · Current Opinion in Oncology · doi:10.1097/01.cco.0000410243.84074.dc · Cited by 18
Lenalidomide in multiple myeloma: current role and future directions
Zeldis, J. B., Knight, R., Jacques, C. J., Tozer, A., & Bizzari, J.-P. (2010) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656561003645611 · Cited by 16
“There is also some evidence to suggest that the duration of lenalidomide therapy may influence mobilization [46,48].”
BackgroundMethodRenal recovery with lenalidomide in a patient with bortezomib-resistant multiple myeloma
Ludwig, H., & Zojer, N. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.31 · Cited by 16
Sheppard, D., Tay, J., Palmer, D. S., Xenocostas, A., Doulaverakis, C., Huebsch, L. B., McDiarmid, S. A., Tinmouth, A. T., Mallick, R., Martin, L., et al. (2015) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2015.11.016 · Cited by 16
Sinha, S., Gertz, M. A., Lacy, M. Q., Dispenzieri, A. A., Hayman, S. R., Buadi, F. K., Dingli, D., Micallef, I. N., Hogan, W. J., Gastineau, D. A., et al. (2011) · Leukemia · doi:10.1038/leu.2011.308 · Cited by 17
Self-citationŞahin, U., & Demirer, T. (2017) · Journal of Clinical Apheresis · doi:10.1002/jca.21591 · Cited by 18
“[43] Kumar S, Dispenzieri A, Lacy MQ, et al.”
BackgroundMechanisms and Treatment of Graft Failure
Lowsky, R., & Messner, H. A. (2015) · Wiley eBooks · doi:10.1002/9781118416426.ch77 · Cited by 18
Laurent, V., Fronteau, C., Antier, C., Dupuis, P., Tessoulin, B., Gastinne, T., Mahé, B., Blin, N., Dubruille, V., Lok, A., et al. (2020) · Bone Marrow Transplantation · doi:10.1038/s41409-020-01033-8 · Cited by 15
Novel immunomodulatory compounds in multiple myeloma
Saini, N. Y., & Mahindra, A. K. (2012) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2013.749235 · Cited by 16
“While cytopenias are common including neutropenia (30 -- 40%), anemia (9 -- 12%) and thrombocytopenia (12 -- 15%), neutropenic fever is seen in less than 5% patients [47].”
BackgroundMultiple myeloma: the disease and its treatment
Gupta, M., Pal, R. N., & Tikoo, D. (2013) · International Journal of Basic & Clinical Pharmacology · doi:10.5455/2319-2003.ijbcp20130302 · Cited by 17
Tageja, N., Korde, N., Kazandjian, D. G., Panch, S. R., Manasanch, E. E., Bhutani, M., Kwok, M., Mailankody, S., Yuan, C. M., Stetler‐Stevenson, M., et al. (2018) · Bone Marrow Transplantation · doi:10.1038/s41409-018-0170-0 · Cited by 14
“Our results in conjunction with recently published studies show that in the era of novel agents, mobilization of HPCs by growth factors alone is an effective alternative to the chemotherapy mobilization [10].”
Benson, D. M., Panzner, K., Hamadani, M., Hofmeister, C. C., Bakan, C. E., Smith, M., Elder, P., Krugh, D., O’Donnell, L. C., & Devine, S. M. (2009) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428190903480728 · Cited by 15
Zheng, G., He, J., Cai, Z., He, D., Luo, Y., Shi, J., Wei, G., Sun, J., & Zheng, W. (2019) · Oncology Letters · doi:10.3892/ol.2019.11177 · Cited by 14
“Number 75 (100) 44 (59) 31 (41) Age, yearsa 38 (16-61) 37.”
BackgroundVaxman, I., Muchtar, E., Jacob, E., Kapoor, P., Kumar, S. K., Dispenzieri, A. A., Buadi, F. K., Dingli, D., Gonsalves, W. I., Kourelis, T., et al. (2021) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2021.06.016 · Cited by 14
Self-citationTodorović, M., Lemajić, N., Jurišić, V., Pantelić, S., Stanisavljevic, D. M., Kurtović, N. K., & Balint, B. (2023) · Translational Oncology · doi:10.1016/j.tranon.2023.101811 · Cited by 13
“Another compounding factor for the responsiveness of PCN patients could be the scarce use of novel drugs for induction like lenalidomide or daratumumab, which are known to impact stem cell mobilization [43, 44].”
BackgroundBigi, F., Manzato, E., Barbato, S., Talarico, M., Puppi, M., Masci, S., Sacchetti, I., Restuccia, R., Iezza, M., Rizzello, I., et al. (2024) · Pharmaceuticals · doi:10.3390/ph17070944 · Cited by 14
“The effect of lenalidomide on stem cell mobilization is thought to be dose-dependent [60], although this remains a matter of debate [61,62], and to be related to myelotoxicity [60], albeit the mechanism underlying myelotoxicity remains unclear.”
BackgroundTerpos, E., Katodritou, E., Symeonidis, A. S., Zagouri, F., Gerofotis, A., Christopoulou, G., Gavriatopoulou, M., Christoulas, D., Ntanasis‐Stathopoulos, I., Kourakli, A., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.32125 · Cited by 14
“More specifically, the number of stem cells collected per patient, and consequently the outcome of ASCT, is similar to other reports in the literature with the use of similar or other induction regimens such as VAD, PAD, dexamethasone, thalidomide and dexamethasone or lenalidomide and dexamethasone.(23,28,34,35) Regar…”
ResultKauer, J., Freundt, E. P., Schmitt, A., Weinhold, N., Mai, E. K., Müller‐Tidow, C., Goldschmidt, H., Raab, M. S., Kriegsmann, K., & Sauer, S. (2023) · BMC Cancer · doi:10.1186/s12885-023-11507-9 · Cited by 14
“Initially, Kumar et al. suggested a negative impact of lenalidomide on stem cell collection in patients treated with lenalidomide-dexamethasone [16].”
BackgroundPartanen, A., Valtola, J., Silvennoinen, R. H., Ropponen, A., Siitonen, T., Putkonen, M., Sankelo, M., Pelkonen, J., Mäntymaa, P., Varmavuo, V., et al. (2017) · Transfusion · doi:10.1111/trf.14220 · Cited by 16
“Variable LEN(1), n 5 26 LEN(2), n 5 34 p value Peak B-CD34(1) cell count, 310(6)/L 80 [12-291] 100 [17-415] 0.”
Kawamura, K., Kikuchi, M., Terasako, K., Wada, H., Yamasaki, R., Ishihara, Y., Sakamoto, K., Ashizawa, M., Sato, M., Machishima, T., et al. (2013) · Transfusion and Apheresis Science · doi:10.1016/j.transci.2013.06.005 · Cited by 13
“We did not use lenalidomide, which may adversely affect PBSC collection [23].”
MethodCowan, A. J., Stevenson, P. A., Green, D. J., Tuazon, S. A., Libby, E. N., Kwok, M., Lee, S., Coffey, D. G., Gopal, A. K., & Holmberg, L. (2021) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2021.04.010 · Cited by 13
Jantunen, E., Partanen, A., Turunen, A., Varmavuo, V., & Silvennoinen, R. H. (2023) · Transfusion Medicine and Hemotherapy · doi:10.1159/000531940 · Cited by 12
“Prolonged lenalido-mide exposure has been associated with a signi fi cant risk of collection failure especially when G-CSF alone mobilization is used [28, 29].”
BackgroundTreatment of newly diagnosed multiple myeloma: advances in current therapy
Kumar, S. K. (2009) · Medical Oncology · doi:10.1007/s12032-009-9370-1 · Cited by 13
“Recent reports suggest that the novel drugs, especially lenalidomide, when used for prolonged periods can impair adequate stem cell harvest [ 43 ].”
BackgroundSelf-citationMina, R., Petrucci, M. T., Bonello, F., Bongarzoni, V., Saccardi, R., Bertuglia, G., Mengarelli, A., Spadaro, A., Lisi, C., Curci, P., et al. (2023) · Haematologica · doi:10.3324/haematol.2023.284023 · Cited by 17
Optimal timing of G-CSF administration for effective autologous stem cell collection
Kim, J. E., Yoo, C., Kim, S. E., Lee, D. H., Kim, S.-W., Lee, J. S., & Suh, C. (2010) · Bone Marrow Transplantation · doi:10.1038/bmt.2010.194 · Cited by 12
Krummradt, F., Sauer, S., Pavel, P., Klein, E.-M., Schmitt, A., Kriegsmann, M., Jordan, K., Müller‐Tidow, C., Goldschmidt, H., Wuchter, P., et al. (2020) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2020.04.030 · Cited by 12
Peripheral blood stem cell mobilization failure
Kurnaz, F., & Kaynar, L. (2015) · Transfusion and Apheresis Science · doi:10.1016/j.transci.2015.05.006 · Cited by 12
Immunomodulatory Agents and Proteasome Inhibitors in the Treatment of Multiple Myeloma
Noonan, K. A., & Colson, K. (2017) · Seminars in Oncology Nursing · doi:10.1016/j.soncn.2017.05.005 · Cited by 14
Poor mobilizer and its countermeasures
Miyazaki, K., & Suzuki, K. (2018) · Transfusion and Apheresis Science · doi:10.1016/j.transci.2018.09.007 · Cited by 12
Dosani, T., Covut, F., Pinto, R., Kim, B., Ali, N. J., Beck, R. C., Maitta, R. W., Downes, K. A., Fox, R. M., Reese, J., et al. (2019) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2019.1573367 · Cited by 12
“sessions required for adequate collection [7].”
Turunen, A., Partanen, A., Valtola, J., Ropponen, A., Siitonen, T., Kuittinen, O. M., Kuitunen, H. K., Putkonen, M., Sankelo, M., Keskinen, L., et al. (2020) · Transfusion · doi:10.1111/trf.15820 · Cited by 12
“The median (range) number of plerixafor injections was 1 (1-2) in MM patients and 2 (1-4) in NHL patients (p = 0.”
BackgroundHow best to use new therapies in multiple myeloma
Dingli, D., & Rajkumar, S. V. (2010) · Blood Reviews · doi:10.1016/j.blre.2010.03.001 · Cited by 14
Self-citationInduction Therapy and Stem Cell Mobilization in Patients with Newly Diagnosed Multiple Myeloma
Ria, R., Reale, A., Solimando, A. G., Mangialardi, G., Moschetta, M., Gelao, L., Iodice, G., & Vacca, A. (2012) · Stem Cells International · doi:10.1155/2012/607260 · Cited by 11
“When combined with dexamethasone and used beyond four cycles, it achieves over 90% PR or better rate [39].”
Metadata
- Authors
- Kumar, S., Dispenzieri, A., Lacy, M. Q., Hayman, S. R., Buadi, F. K., Gastineau, D. A., Litzow, M. R., Fonseca, R., Roy, V, Rajkumar, S. V., & Gertz, M. A.
- Affiliations
- Mayo Clinic (US)
- Mayo Clinic in Florida (US)
- Corresponding author
- Kumar, S
- ORCID
- Venue
- Leukemia
- Published
- 2007-06-21
- Volume
- 21
- Issue
- 9
- Pages
- 2035-2042
- ISSN
- 0887-6924 (ISSN-L)
- 1476-5551
- OpenAlex
- W2036985459
- Semantic Scholar
- 831eb40600d3fcbfc29f2b9cc655e7c78f420e1f
- Cited by
- 351
- References
- 35
- Citations by year
- 2026: 6 · 2025: 6 · 2024: 10 · 2023: 17 · 2022: 15 · 2021: 20 · 2020: 18 · 2019: 16 · 2018: 9 · 2017: 17 · 2016: 15 · 2015: 23 · 2014: 15 · 2013: 29 · 2012: 27
- FWCI
- 17.46
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Leukemia (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Mayo Clinic
- Mayo Foundation for Medical Education and Research
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Mesenchymal stem cell research
- Keywords
- lenalidomide, peripheral blood stem cell mobilization, stem cell engraftment, multiple myeloma, newly diagnosed multiple myeloma, granulocyte colony-stimulating factor, CD34+ cell yield, apheresis, VAD chemotherapy, bortezomib, mobilization failure
- MeSH terms
- Lenalidomide, Adult, Aged, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Combined Modality Therapy, Dexamethasone, Doxorubicin, Female, Humans, Male, Middle Aged, Multiple Myeloma, Thalidomide, Vincristine, Hematopoietic Stem Cell Transplantation, Antineoplastic Agents, Hormonal, Hematopoietic Stem Cell Mobilization, Angiogenesis Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.